Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 10/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777120 | 0.95 | NPY5R (0.54) | NPY5RBCL2RIPK1HRH3 | |
| Trifluoroacetic Acid SCHEMBL4774586 | 0.86 | MAPT (0.51) | SLC2A1HRH3 | |
| Trifluoroacetic Acid SCHEMBL4775487 | 0.86 | KMT2A (0.53) | SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL4767895 | 0.85 | AURKA (0.50) | SLC2A1HRH3 | |
| Trifluoroacetic Acid SCHEMBL4764992 | 0.85 | TP53 (0.51) | SLC2A1HRH3 | |
| Trifluoroacetic Acid SCHEMBL4771967 | 0.83 | SLC2A1 (0.45) | SLC2A1HRH3 | |
| Trifluoroacetic Acid SCHEMBL4770119 | 0.83 | MEN1 (0.52) | SLC2A1HRH3 | |
| Trifluoroacetic Acid SCHEMBL4765180 | 0.82 | POLB (0.52) | SLC2A1HRH3 | |
| Trifluoroacetic Acid SCHEMBL4771045 | 0.82 | RAB9A (0.53) | SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL4775303 | 0.82 | ALDH1A1 (0.52) | SLC2A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | NPY5R 754/4885BCL2 1599/4885RIPK1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.